Jazz Pharmaceuticals plc has named Thomas Riga as Chief Business Officer, effective January 1, 2026. Riga, who joined Jazz in April 2025 through the acquisition of Chimerix Inc., brings more than 25 years of commercial and operational experience in the pharmaceutical industry. During his tenure at Chimerix, he directed the successful sale of the company to Jazz and oversaw the U.S. approval and launch of Modeyso™ (dordaviprone), the first therapy for H3K27M-mutant diffuse midline glioma, a condition affecting approximately 2,000 children and young adults annually. At Jazz, he will lead the execution of corporate development initiatives and drive strategic partnerships, building on his track record of leading over $2 billion in business development transactions over the past five years.

Jazz Pharmaceuticals reported positive Phase 3 data for Ziihera (zanidatamab-hrii) in combination with tislelizumab and chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma. The triplet regimen achieved a median overall survival of 26.4 months, representing the longest OS reported to date in a Phase 3 GEA trial and a 28% reduction in the risk of death compared to standard therapy. The doublet regimen of Ziihera plus chemotherapy also demonstrated robust efficacy, with a median OS of 24.4 months. Following the announcement, Jazz Pharmaceuticals shares advanced by 2.07%, underscoring investor confidence in the company’s oncology pipeline.